Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0044-1786815
Identification of a Novel Intronic Mutation in VMA21 Associated with a Classical Form of X-Linked Myopathy with Autophagy
Abstract
Introduction VMA21-related myopathy is one of the rare forms of slowly progressive myopathy observed in males. Till now, there have been only a handful of reports, mainly from Europe and America, and two reports from India.
Method Here, we describe a case of genetically confirmed VMA21-associated myopathy with clinical, histopathological, and imaging features with a list of known VMA21 mutations.
Results A 29-year-old man had the onset of symptoms at 18 years of age with features of proximal lower limb weakness. Muscle magnetic resonance imaging showed the preferential involvement of vasti and adductor magnus. A biopsy of the left quadriceps femoris showed features of autophagic vacuolar myopathy with vacuoles containing granular eosinophilic materials. In targeted next-generation sequencing, hemizygous mutation in the 3′ splice site of intron 2 of the VMA21 gene (c.164–7 T > A) was identified and confirmed the diagnosis of X-linked myopathy with excessive autophagy.
Conclusion This report expands the phenotypic and genotypic profile of VMA21-related myopathy, with a yet unreported mutation in India.
#
Introduction
X-linked myopathy with excessive autophagy (XMEA) is one of the early-onset myopathies that predominantly affects males.[1] It results mainly from a genetic defect in VMA21 leading to alteration in chaperone assembly of vacuolar ATPase and increases the lysosomal pH,[2] hence also called as VMA21-related myopathy. Histopathologically, it is characterized by autophagic vacuoles with sarcolemmal features.[3] The onset of symptoms is usually as early as in the second decade, with variable severity.[4] The features of VMA21-related myopathy closely resemble those with congenital autophagic vacuolar myopathy (CAVM); however, clinical presentation is largely confined to term neonates with respiratory failure requiring ventilatory support.[5] There are fewer than 50 cases reported worldwide. Here, we present the clinical, radiological, histopathological, and genetic features of a young man with XMEA from India.
#
Case History
A 29-year-old man born from nonconsanguineous parents was evaluated in 2019. He presented with gradually progressive weakness of lower limbs from 18 years of age. Initially, he noticed difficulty while cycling and running fast. Over the next year, he started experiencing buckling episodes and falls while walking. By 25 years of age, he developed difficulty rising from the floor and climbing stairs. There was no feature of distal limb weakness, myalgia, cramps, contractures, or cardiac symptoms. There was no significant positive family history ([Fig. 1]).
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-1.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
On examination, he has mild calf hypertrophy. The muscle power, according to modified Medical Research Council grading, was as follows: infraspinatus (4), Iliopsoas (4), hip adductors (4 + ), quadriceps (4), and the rest of the power examination was normal. Tendon reflexes were normal except for hypoactive knee jerks. There was no scapular winging or muscle contractures. The creatine kinase level was 6630 IU/L (normal: 20–200 U/L). The electrocardiogram and two-dimensional echocardiography were normal. Nerve conduction study was normal.
Muscle magnetic resonance imaging (MRI) showed bilateral symmetric volume loss with fatty replacement of the proximal thigh muscles, preferentially involving the vasti and adductor magnus with relative sparing of the rectus femoris. In the thigh muscles, there was no aberrant short tau inversion recovery signal intensity ([Fig. 2]).
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-2.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Open muscle biopsy was done from the left quadriceps femoris muscle and analyzed using hematoxylin and eosin and Masson's trichrome stains. Histopathology showed fiber size variation with scattered atrophic angulated fibers and a few hypertrophic fibers, along with internalized nuclei and splitting. A few of the fibers also showed vacuoles containing granular eosinophilic material within it ([Fig. 3]).
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-3.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Exome sequencing showed hemizygous mutation in the VMA21 gene (chrX:g.150573381T > A, hg19) affecting the seventh nucleotide position upstream of exon 3 (c.164–7T > A; ENST00000330374.6) in the 3′ splice site of intron 2 ([Fig. 4]). In-silico analysis using spliceAI (https://spliceailookup.broadinstitute.org/) predicted loss of canonical acceptor site at intron2/exon3 junction (Δ score: 0.39; threshold ≥ 0.2).[6]
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-4.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
#
Discussion
Our patient had onset of symptoms in the second decade with features of indolent proximal lower limb involvement and imaging features suggesting preferential involvement of adductor component of thigh muscles and also classical histopathological findings with next-generation sequencing confirming the diagnosis. Though there are many case reports from Europe and America, there are only a few cases from Asia (Comparison with previous studies is given in [Table 1]).[1] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17]
S.no |
Authors/ year |
Ethnicity/ total no. of patients included |
Age at onset (years) |
Age at presentation (years) |
Clinical presentation |
Disease course |
Consanguinity/ family history |
Muscle biopsy |
Muscle MRI |
Genotype features |
---|---|---|---|---|---|---|---|---|---|---|
1 |
Rajeshwari et al/ 2022[7] |
Indian/1 |
6 |
8 |
Proximal lower limb weakness |
Slowly progressive |
−/− |
Fiber size variation with autophagic vacuoles and MAC deposits. |
– |
Single nucleotide substitution at the splice branch point of intron1 (X:150572076A> T; c. 54–27A> T) |
2 |
Rao et al 2019[8] |
Indian/1 |
Early childhood |
5 |
Delayed motor milestones with proximal lower limb and facial weakness |
Slowly progressive |
−/− |
Myopathic changes with autophagic vacuoles |
– |
– |
3 |
Crockett et al 2014[3] |
American/1 |
55 |
65 |
Proximal lower limb weakness |
Slowly progressive |
−/+ (elder brother with limb weakness since mid-40s and wheel chair bound by lates 50's.) |
Numerous cytoplasmic vacuoles staining positively for extracellular matrix protein Perlecan but negative for collagen VI Large, debris-containing intracellular vacuolar inclusions that focally disrupted sarcomeric structure of the muscle fibers representing autophagic vacuoles. |
– |
Substitution of a pyrimidine into a purine, c.164–7T > G |
4 |
Alon et al 2021[9] |
Jewish Israeli/1 |
20 |
25 |
Proximal lower limb weakness |
Slowly progressive |
+/Maternal grandfather (onset-20 y) and male cousin (10 y) |
Autophagic vacuoles and MAC deposits. |
Fatty replacement of the vastus lateralis, semimembranosus, and gluteus maximus muscles |
hemizygous mutation c.272G > C on the 3rd exon |
5 |
Ruggieri et al 2015[10] |
I: Italian, II: European-Australian/2 |
I: birth II: early childhood |
I: 14 II: 21 |
I: Hypotonia with respiratory distress followed by reduced muscle bulk in upper limbs and thoracic muscles with febrile seizures. II: delayed milestones followed by proximal upper and lower limb weakness. |
Slowly progressive |
I: −/− II: −/maternal uncle (onset: childhood) |
I & II: Markedly variable fiber size. Increase in endomysial and perimysial fat and fibrous connective tissue, Multiple basophilic vacuoles in numerous fibers. |
− |
I: 92 bp microdeletion, c.*13_*104del, in 3′UTR. II: 9 bp microdeletion, c.54–16_54–8del, upstream of exon 2 |
6 |
Cotta et al 2020[11] |
Brazilian/2 |
I: 4 II: 7 |
I: 7 II: 20 |
I: Proximal lower limb weakness II: Proximal lower limb weakness |
Slowly progressive |
I: −/four male cousins, maternal uncle, II: −/− |
I & II: Intrasarcoplasmic autophagic vacuoles with sarcolemmal features autophagic vacuoles |
I: Adductor magnus, preferential peripheral vastus lateralis involvement, partial Rectus femoris, and peripheral Tibialis anterior and soleus muscles involvement. II: Adductor magnus, superficial vastus lateralis, peripheral rectus femoris. |
I: c.163 + 4A > G II: c.272G > C |
7 |
Pegat et al 2022[12] |
French/1 |
11 |
16 |
Tiptoe walking followed by proximal lower limb weakness |
Slowly progressive |
−/− |
Numerous cytoplasmic autophagic vacuoles strongly positive for PAS and phosphatidic acid. p62 and TDP 43) were also positive in cytoplasmic autophagic vacuoles. |
Fatty infiltration of both anterior and posterior thigh. |
Unreported, intronic, single-nucleotide substitution c.164–20T > A. |
8 |
Blanco-Arias et al 2023[13] |
Spanish/4 |
At birth |
One died during first hour of life, other three in second and third decades of life. |
Severe muscle weakness with respiratory failure and death in early childhood |
Rapidly progressive |
−/all four patients from same family |
Autophagic vacuoles and MAC deposits. |
– |
c.294C > T (Gly98 = ) |
9 |
Chabrol et al 2001[14] |
French/ 5 families – 8 patients |
F-1: early childhood F-2: early childhood F-3: 12 y F-4: birth F-5: birth |
F-1: 5 F-2: 5 F-3: 17 F-4: 3 F-5: 5 |
F-1: generalized fatigue. F-2: proximal lower limb weakness. F-3: proximal lower limb weakness. F-4: persistently elevated CK. F-5: infantile hypotonia followed by proximal lower limb weakness with a rigid spine. |
F-1: nonprogressive. F-2: slowly progressive. F-3: slowly progressive. F-4: nonprogressive. |
F-1: −/− F-2: −/− F-3: −/+ F-4: −/− F5: −/− |
Increased variation in muscle fiber size, round atrophic fibers. Vacuoles were present. |
– |
– |
10 |
Kalimo H et al 1988[1] |
Finnish/3 |
P-1: 5 P-2: 6 P-3: childhood |
P-1: 13 P-2: 8 P-3: not examined clinically |
All proximal lower limb weakness |
P-1: slowly progressive. P-2: slowly progressive. P-3: NA |
−/all three patients from the same family |
– |
– |
– |
11 |
Villanova M et al 1995[15] |
French/4 |
P-1: childhood P-2:18–19 P-3: 20 P-4: second decade |
P-1: 25 P-2: 56 P-3: not examined P-4: 64 |
All proximal lower limb weakness |
All slowly progressive. |
−/ all four patients from same family |
P-1: Increased variation in muscle fiber size, round atrophic fibers. Vacuoles were present. P-2: Increased variation in muscle fiber size, round atrophic fibers. Vacuoles were present. P-3: ND P-4: ND |
– |
– |
12 |
Kurashige et al 2013[16] |
Japanese/3 |
F-1: 6 F-2: childhood F-3: childhood |
F-1: 52 F-2:43 F-3:47 |
All proximal lower limb weakness |
All slowly progressive. |
F-1: −/two maternal uncles F-2 is maternal uncle of F-3 |
F-1: Muscle fibers with vacuoles containing delicate basophilic debris F-2: Muscle fibers with vacuoles containing delicate basophilic debris F-3: ND |
F-1: Atrophy and fatty degeneration of femoral muscles, Rectus femoris spared F-2: ND F-3: ND |
F-1: Hemizygous c.164–7T > G mutation F-2: ND F-3: ND |
13 |
Mercier et al 2015[4] |
French/4 |
F-1: 12 F-2: 7 F-3: 18 F-4: third decade |
F-1: 43 F-2: 14 F-3: 31 F-4: 33 |
F-1: Proximal lower limb weakness F-2: Toe walking F-3: Proximal lower limb weakness F-4: Proximal lower limb weakness |
All slowly progressive. |
F-1: −/− F-2: −/nephew F-3 and F4 are brothers. |
F-1: Moderate myopathic pattern, with irregular fiber size, fiber splitting, and internal nuclei, Small vacuoles were observed. F-2: ND F-3: Moderate myopathic pattern, with irregular fiber size, fiber splitting, and internal nuclei, Small vacuoles were observed. F-4: Moderate myopathic pattern, with irregular fiber size, fiber splitting, and internal nuclei, Small vacuoles |
F-1: Diffuse fatty degeneration in all muscles with more severe involvement in lower than in upper limbs and in proximal than in distal regions. F-2: Early fatty degeneration present in the pelvic girdle. F-3: Prominent involvement of the pelvic girdle and almost all thigh muscles. Shoulder girdle and proximal upper limbs are also affected. F-4: ND |
F-1: intronic mutation (c.163 + 3A > G). F-2: intronic mutation (c.163 + 3A > G). F-3: intronic mutation (c.163 + 3A > G). F-4: ND |
14 |
Munteanu et al 2016[5] |
Japanese/1 |
2 mo |
– |
Floppy infant |
NA |
−/− |
Electron-dense-debris-filled vacuoles, deposition of complement membrane attack complex on vacuoles, and multiplication of the basal lamina |
– |
c.164–6T > G mutation |
15 |
Fernandes et al 2020[17] |
Brazil/1 |
2 |
5 |
Distal lower limb weakness with electrocardiogram showed incomplete right bundle branch conduction |
Slowly progressive. |
−/Five males affected |
presence of vacuoles in muscle fibers, as observed by the basophilic inclusions |
– |
c.54–30_54–27delinsT variant |
16 |
Our study/ 2023 |
Indian/1 |
18 |
29 |
Proximal lower limb weakness |
Slowly progressive. |
−/− |
Variation in fiber size including atrophic angulated fibers and a few hypertrophic fibers along with internalized nuclei. Few of the fibers also showed vacuoles with granular eosinophilic material within it. |
Diffuse fatty atrophy and volume loss of bilateral anterior compartment of thighs with relative sparing of medial compartment muscles. |
Hemizygous splice variation c.164–7T > A |
XMEA affects males and has a slowly progressive proximal limb muscle weakness and normal cardiac function with onset ranging from childhood to adulthood.[10] VMA21 is an assembly chaperone for the principal mammalian proton pump required for lysosome acidification. Due to the genetic defect in VMA21, alteration in lysosomal acidification leads to a block in steps of macroautophagy and accumulation of autophagosomes. This results in vacuole formation filled with debris in the muscles.[2] These vacuolar changes can also be observed in Danon's disease; however, calcium deposition, basal lamina reduplication, and absence of cardiomyopathy suggest XMEA.[1] [18]
Most VMA21 mutations have been reported to affect normal splicing, predominantly occurring in the introns 1 and 2. One missense, c.272G > C, and another synonymous mutation, c.294C > T, while present in exon 3 have also been shown to affect splicing ([12] [13]). Mis-splicing mutations lead to the reduction of mRNA and, in turn, reduced expression of VMA21 protein.[2] Clinical phenotype severity has been described as directly related to the extent of mRNA expression reduction.[12] [13] Intronic VMA21 mutations affecting the polypyrimidine tract in intron 2 adjacent to the acceptor site (c.164–6T > G; c.164–7T > G; c.164–20T > A) have been reported in multiple patients.[3] [5] [16] The mutations -6T > G and -20T > A pyrimidine-to-purine substitutions have been associated with severe phenotypes of congenital onset CAVM and childhood onset with relatively severe progression, respectively.[5] [12] In comparison, c.164–7T > G has been reported with milder XMEA phenotype with variable onset ranging from childhood to late adulthood (>50 years).[3] [16] The pyrimidine-to-purine substitution at -7 position in intron 2 has been described to reduce the binding efficacy of the U2AF splice factor, causing abnormal splice recognition at the acceptor site.[2] Our patient also had a novel pyrimidine-to-purine change of T > A at the same -7 position reported in earlier XMEA patients. While we could not check the mRNA expression levels in our patient, based on in-silico predictions, we presume a similar impact as in previous patients with -7T > G substitution. This correlated with our patient's milder XMEA phenotype with second-decade onset.
The age of onset is quite variable, though typically described as childhood onset. There are various reports on adult-onset myopathy, as noted in our patient,[4] [9] [15] with the oldest being onset in the seventh decade, as reported by Crockett et al.[3] It typically affects males and spares carrier females. The phenotypic spectrum extends from floppy infant delayed milestones to proximal limb-girdle and respiratory muscle weakness. Usually, extra skeletal muscle involvement does not occur. However, Fernandes et al described a patient with childhood-onset distal lower limb weakness with incomplete right bundle branch block.[17]
The earliest and most frequently affected muscles in XMEA are the pelvic girdle and proximal thigh muscles, with the anterior compartment more involved than the posterior compartment, mimicking limb girdle muscular dystrophy pattern. MRI pattern of muscle in XMEA typically shows early involvement of the vasti, adductor magnus, and soleus with relative sparing of the rectus femoris and tibialis anterior.[5] Although muscle imaging shows thigh involvement in almost all patients, few patients show preferential involvement of the adductor group.[1] [16] However, selective involvement of peripheral vastus lateralis, partial rectus femoris, and peripheral tibialis anterior muscle has also recently been described.[11] Our patient also had typical findings as described in previous reports with fatty infiltration of the vasti and adductor magnus and sparing of rectus femoris, showing that imaging pattern could be a strong indicator toward XMEA diagnosis in clinically suspected patients.
Histopathological analysis of skeletal muscle may show muscle fibers with sarcoplasmic vacuoles containing degraded organelles, debris, and calcium crystals. These vacuoles can be seen within the muscle fibers' interior depths or superficially close to the sarcolemma.[18] Generally, inflammation, necrosis, or apoptosis are not observed. Instead, myofiber demise occurs through a novel form of autophagic cell death characterized by giant autophagic vacuoles, 2 to 10 µm in size, encircling sections of cytoplasm, including organelles. These vacuoles contain lysosomal hydrolases with incomplete contents of digestion. Definitive diagnosis includes clinical presentation and genetic mutation identification.
#
Conclusion
Here, we report an Indian case of VMA21-related myopathy that adds to our knowledge of XMEA phenotype-genotype spectrum. The pathological features and clinical spectrum of XMEA are large and overlap with other disorders. It also highlights the preferential involvement of thigh muscles with distinctive sparing of rectus femoris, which may aid in the diagnosis of this rare myopathy.
#
#
Conflict of Interest
None declared.
Prior Publication
None.
-
References
- 1 Kalimo H, Savontaus ML, Lang H. et al. X-linked myopathy with excessive autophagy: a new hereditary muscle disease. Ann Neurol 1988; 23 (03) 258-265
- 2 Ramachandran N, Munteanu I, Wang P. et al. VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathol 2013; 125 (03) 439-457
- 3 Crockett CD, Ruggieri A, Gujrati M. et al. Late adult-onset of X-linked myopathy with excessive autophagy. Muscle Nerve 2014; 50 (01) 138-144
- 4 Mercier S, Magot A, Caillon F. et al. Muscle magnetic resonance imaging abnormalities in X-linked myopathy with excessive autophagy. Muscle Nerve 2015; 52 (04) 673-680
- 5 Munteanu I, Ramachandran N, Ruggieri A, Awaya T, Nishino I, Minassian BA. Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy. Neurology 2015; 84 (16) 1714-1716
- 6 Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF. et al. Predicting splicing from primary sequence with deep learning. Cell 2019; 176 (03) 535-548.e24
- 7 Rajeshwari M, Dhiman N, Chakrabarty B. et al. X-linked myopathy with excessive autophagy—a rare cause of vacuolar myopathy in children. Neurol India 2022; 70 (04) 1643-1648
- 8 Rao S, Chandra SR, Narayanappa G. X-linked myopathy with excessive autophagy; a case report. Neurol India 2019; 67 (05) 1344-1346
- 9 Alon T, Sadeh M, Lev D, Dabby R. X-linked myopathy with excessive autophagy: First report of an Israeli family presenting with late onset lower limb girdle weakness. Neuromuscul Disord 2021; 31 (09) 854-858
- 10 Ruggieri A, Ramachandran N, Wang P. et al. Non-coding VMA21 deletions cause X-linked myopathy with excessive autophagy. Neuromuscul Disord 2015; 25 (03) 207-211
- 11 Cotta A, Carvalho E, da-Cunha-Junior AL. et al. Clinical, imaging, morphologic, and molecular features of X-linked VMA21-related myopathy in two unrelated Brazilian families. J Neurol Sci 2020; 415: 116977
- 12 Pegat A, Streichenberger N, Lacoste N. et al. Novel Intronic Mutation in VMA21 causing severe phenotype of X-Linked myopathy with excessive autophagy-case report. Genes (Basel) 2022; 13 (12) 2245
- 13 Blanco-Arias P, Medina Martínez I, Arrabal Fernández L. et al. Severe congenital X-linked myopathy with excessive autophagy secondary to an apparently synonymous but pathogenic novel variant. Neuromuscul Disord 2023; 33 (07) 557-561
- 14 Chabrol B, Figarella-Branger D, Coquet M. et al. X-linked myopathy with excessive autophagy: a clinicopathological study of five new families. Neuromuscul Disord 2001; 11 (04) 376-388
- 15 Villanova M, Louboutin JP, Chateau D. et al. X-linked vacuolated myopathy: complement membrane attack complex on surface membrane of injured muscle fibers. Ann Neurol 1995; 37 (05) 637-645
- 16 Kurashige T, Takahashi T, Yamazaki Y. et al. Elevated urinary β2 microglobulin in the first identified Japanese family afflicted by X-linked myopathy with excessive autophagy. Neuromuscul Disord 2013; 23 (11) 911-916
- 17 Fernandes SA, Almeida CF, Souza LS. et al. Altered in vitro muscle differentiation in X-linked myopathy with excessive autophagy. Dis Model Mech 2020; 13 (02) dmm041244
- 18 Louboutin JP, Villanova M, Lucas-Héron B, Fardeau M. X-linked vacuolated myopathy: membrane attack complex deposition on muscle fiber membranes with calcium accumulation on sarcolemma. Ann Neurol 1997; 41 (01) 117-120
Address for correspondence
Publication History
Article published online:
10 May 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Kalimo H, Savontaus ML, Lang H. et al. X-linked myopathy with excessive autophagy: a new hereditary muscle disease. Ann Neurol 1988; 23 (03) 258-265
- 2 Ramachandran N, Munteanu I, Wang P. et al. VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy. Acta Neuropathol 2013; 125 (03) 439-457
- 3 Crockett CD, Ruggieri A, Gujrati M. et al. Late adult-onset of X-linked myopathy with excessive autophagy. Muscle Nerve 2014; 50 (01) 138-144
- 4 Mercier S, Magot A, Caillon F. et al. Muscle magnetic resonance imaging abnormalities in X-linked myopathy with excessive autophagy. Muscle Nerve 2015; 52 (04) 673-680
- 5 Munteanu I, Ramachandran N, Ruggieri A, Awaya T, Nishino I, Minassian BA. Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy. Neurology 2015; 84 (16) 1714-1716
- 6 Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF. et al. Predicting splicing from primary sequence with deep learning. Cell 2019; 176 (03) 535-548.e24
- 7 Rajeshwari M, Dhiman N, Chakrabarty B. et al. X-linked myopathy with excessive autophagy—a rare cause of vacuolar myopathy in children. Neurol India 2022; 70 (04) 1643-1648
- 8 Rao S, Chandra SR, Narayanappa G. X-linked myopathy with excessive autophagy; a case report. Neurol India 2019; 67 (05) 1344-1346
- 9 Alon T, Sadeh M, Lev D, Dabby R. X-linked myopathy with excessive autophagy: First report of an Israeli family presenting with late onset lower limb girdle weakness. Neuromuscul Disord 2021; 31 (09) 854-858
- 10 Ruggieri A, Ramachandran N, Wang P. et al. Non-coding VMA21 deletions cause X-linked myopathy with excessive autophagy. Neuromuscul Disord 2015; 25 (03) 207-211
- 11 Cotta A, Carvalho E, da-Cunha-Junior AL. et al. Clinical, imaging, morphologic, and molecular features of X-linked VMA21-related myopathy in two unrelated Brazilian families. J Neurol Sci 2020; 415: 116977
- 12 Pegat A, Streichenberger N, Lacoste N. et al. Novel Intronic Mutation in VMA21 causing severe phenotype of X-Linked myopathy with excessive autophagy-case report. Genes (Basel) 2022; 13 (12) 2245
- 13 Blanco-Arias P, Medina Martínez I, Arrabal Fernández L. et al. Severe congenital X-linked myopathy with excessive autophagy secondary to an apparently synonymous but pathogenic novel variant. Neuromuscul Disord 2023; 33 (07) 557-561
- 14 Chabrol B, Figarella-Branger D, Coquet M. et al. X-linked myopathy with excessive autophagy: a clinicopathological study of five new families. Neuromuscul Disord 2001; 11 (04) 376-388
- 15 Villanova M, Louboutin JP, Chateau D. et al. X-linked vacuolated myopathy: complement membrane attack complex on surface membrane of injured muscle fibers. Ann Neurol 1995; 37 (05) 637-645
- 16 Kurashige T, Takahashi T, Yamazaki Y. et al. Elevated urinary β2 microglobulin in the first identified Japanese family afflicted by X-linked myopathy with excessive autophagy. Neuromuscul Disord 2013; 23 (11) 911-916
- 17 Fernandes SA, Almeida CF, Souza LS. et al. Altered in vitro muscle differentiation in X-linked myopathy with excessive autophagy. Dis Model Mech 2020; 13 (02) dmm041244
- 18 Louboutin JP, Villanova M, Lucas-Héron B, Fardeau M. X-linked vacuolated myopathy: membrane attack complex deposition on muscle fiber membranes with calcium accumulation on sarcolemma. Ann Neurol 1997; 41 (01) 117-120
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-1.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-2.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-3.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/10.1055-s-00046370/202402/thumbnails/10-1055-s-0044-1786815-i2400013-4.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)